Sickle Cell Patient with Pain
Patient with known SCD presents with acute pain episode
All Pathways
Hematology & OncologyEmergency
Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020)
Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020): Sickle Cell Patient with Pain → Immediate Triage (ESI-2) → Initial Assessment → Signs of ACS or...
Pathway Overview
12 steps
Algorithm Steps
12 total
01Start 02Action Immediate Triage (ESI-2)
High acuity - target analgesic within 60 minutes
- Assign ESI-2 triage level
- Target door-to-analgesia <60 minutes
- Obtain IV access
- Check vital signs including SpO2
03Action Initial Assessment
Evaluate for complications and pain severity
- Pain assessment (0-10 scale)
- Respiratory assessment (ACS screening)
- Fever evaluation
- Neurological assessment (stroke screening)
- Hydration status
04Decision Signs of ACS or Stroke?
Screen for life-threatening complications
- ACS: Chest pain, fever, hypoxia, new infiltrate
- Stroke: Focal neuro deficits, altered mental status
- Priapism >4 hours
- Splenic sequestration (LUQ pain, falling Hgb)
05Warning Critical Complication
Immediate specialist consultation
- ACS: Transfusion, antibiotics, incentive spirometry
- Stroke: Exchange transfusion, neurology consult
- Priapism: Urology consult, aspiration
- Sequestration: Transfusion, possible splenectomy
06Outcome Admit for Ongoing Management
Inpatient pain management and monitoring
07Action Rapid Opioid Analgesia
IV opioids within 60 minutes of arrival
- Use patient's individualized pain protocol if available
- Morphine 0.1-0.15 mg/kg IV or equivalent
- Hydromorphone 0.015-0.02 mg/kg IV alternative
- Reassess pain every 15-30 minutes
- Re-dose opioid every 15-30 min until controlled
08Action Adjunct Therapies
Supportive care measures
- IV fluids: isotonic, avoid overhydration
- Supplemental O2 if SpO2 <95%
- Incentive spirometry every 2 hours while awake
- NSAIDs (ketorolac) if no contraindication
- Antiemetics as needed
09Decision Pain Controlled After 2-3 Doses?
Assess response to initial therapy
10Action Escalate Therapy
Consider admission and PCA
- Admit to hospital
- Consider PCA (patient-controlled analgesia)
- Hematology consultation
- Consider transfusion if Hgb significantly below baseline
- Evaluate for underlying infection
- Path rejoins step 06Shared downstream outcome
11Action Consider Discharge
If pain controlled and stable
- Transition to oral opioids
- Ensure adequate supply of pain medications
- Hydroxyurea adherence counseling
- Follow-up with hematology within 7 days
- Return precautions: fever, worsening pain, SOB
12Outcome Discharge Home
With oral analgesics and close follow-up
Guideline Source
American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address pediatric-specific dosing in detail
- Requires institutional opioid protocols for specific dosing
- Does not cover gene therapy or curative treatments
- Acute chest syndrome management is simplified
Contraindicated Populations
pregnancy_third_trimester_without_specialist
Applicable Regions
USEUGlobal
EU: Adapt to local opioid prescribing regulations
US: Follow ASH 2020 guidelines for pain management
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Absolute Neutrophil Count (ANC)
Absolute neutrophil count from CBC for neutropenia grading
Open page
Compare
AttendMe.ai vs OpenEvidence
See how this pathway workflow compares against OpenEvidence.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020)?
The Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020) is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain.
What guideline is the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020) based on?
This algorithm is based on American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain (DOI: 10.1182/bloodadvances.2020001851).
What are the limitations of the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020)?
Known limitations include: Does not address pediatric-specific dosing in detail; Requires institutional opioid protocols for specific dosing; Does not cover gene therapy or curative treatments; Acute chest syndrome management is simplified. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free